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A subgroup of acute leukemia with morphology resembling acute promyelocytic leuke-
mia (APL) shows variant translocations involving RARA and has a different morphology 
from that of classical APL. The variant APL with t(11;17)(q23;q12); ZBTB16-RARA sub-
group has been reported to have leukemic cells with regular nuclei, many granules, ab-
sence of Auer rods, an increased number of Pelgeroid neutrophils, strong myeloperox-
idase (MPO) activity, and all-trans-retinoic-acid (ATRA) resistance. Here, we report a case 
of variant APL with t(11;17)(q23;q12); ZBTB16-RARA showing typical morphological fea-
tures of classical APL, including numerous Auer rods and faggot cells. The leukemic cells 
expressed CD13, CD33, CD117, human leukocyte antigen (HLA)-DR, and cytoplas-
mic-MPO on the immunophenotyping study. The diagnosis was confirmed by cytoge-
netic and molecular studies. To distinguish variant APL cases from classical APL cases, 
regardless of whether morphologically the findings are consistent with those of classical 
APL, combining morphologic, immunophenotypic, cytogenetic, and molecular studies 
before chemotherapy is very important.
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INTRODUCTION
Acute promyelocytic leukemia (APL) with t(15;17)(q22;q12); 
PML-RARA is characterized by the presence of promyelo-
cytes and multiple Auer rods, hemorrhagic tendency, and 
PML/RARA fusion mRNA [1-4]. A subgroup of acute leuke-
mia that has a similar morphology as APL shows variant 
translocations involving RARA. These variant fusion partners 
include ZBTB16 at 11q23, NUMA1 at 11q13, NPM1 at 5q35, 
and  STAT5B at 17q11.2 [5-8]. Some of the variant APL 
with t(11;17)(q23;q21) cases that are associated with the 
ZBTB16-RARA fusion gene have been reported as being 
resistant to all-trans-retinoic acid (ATRA) [9]. Therefore, 
differential diagnosis of variant APL with t(11;17)(q23;q12) 
from classical APL with t(15;17)(q22;q12); PML-RARA is 
very important. Variant APL cases usually show different 
morphological characteristics. The variant APL with t(11;17) 
(q23;q12);  ZBTB16-RARA subgroup has been reported to 
have leukemic cells with regular nuclei, many granules, ab-
sence of Auer rods, an increased number of Pelgeroid neu-
trophils, and strong myeloperoxidase (MPO) activity [10]. 
Therefore, whe n leukemic cells show typical morphology 
of classical APL with t(15;17)(q22;q12); PML-RARA, the 
possibility of variant APL is very low. We report a case 
of variant APL with the t(11;17)(q23;q12); ZBTB16-RARA 
showing typical morphology of classical APL.
CASE REPORT
In January 2010, a 52-year-old man was referred to our 
hospital because of pancytopenia. Complete blood count 
(CBC) showed pancytopenia with white blood cells, 1,620/μL 
(segment neutrophils, 12.3%; lymphocytes, 60.5%; mono-
cytes, 27.2%; eosinophils, ＜1%; basophils, ＜1%; leukemic 
cells, 8%); hemoglobin, 8.8 g/dL; and platelets, 98,000/μL. 
Bone marrow biopsy revealed about 100% cellularity, and 
that 80% of the nucleated elements were leukemic cells. 
The leukemic cells showed medium to large size, irregular 
shape, finely chromatinized nuclei with distinct nucleoli, 
and moderate amount of blue cytoplasm with azurophilic Korean J Hematol 2010;45:133-5.
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Fig. 1. Bone marrow aspirates 
showing typical acute promye-
locytic leukemia morphology, in-
cluding numerous leukemic pro-
myelocytes with faggot cells (A) 
Wright stain; ×1,000 and strong 
myeloperoxidase activity (B) myel-
operoxidase stain; ×1,000).
Fig. 2. In the first PCR (A) for 
screening of leukemia-associated 
genes, there is a positive band in 
lane 8 (between 250-300 bp). In 
the split-out reaction (B) using a 
single specific primer pair, a 
t(11;17)(q23;q21);  ZBTB16-RARA
fusion (285 bp) is confirmed, as 
revealed by the bands in lane 8A.
Fig. 3. The karyotype of the patient was 46,XY,t(11;17)(q23;q21)[17]/ 
46,XY[3].
granules. The leukemic cells showed multiple Auer rods 
and frequently showed faggot cells (Fig. 1A). They were 
strongly positive to MPO stain (Fig. 1B). The leukemic cells 
expressed CD13, CD33, CD117, human leukocyte antigen 
(HLA)-DR, and cytoplasmic-MPO, as revealed by the im-
munophenotyping study. ZBTB16-RARA translocation was 
detected on the leukemia gene screening test by reverse 
transcription-nested polymerase chain reaction (Fig. 2; 
Hemavision, DNA technology, Denmark). Cytogenetic study 
revealed t(11;17)(q23;q21) (Fig. 3). The patient is being treat-
ed with chemotherapy without ATRA.
DISCUSSION
Most APLs show typical morphology, including irregular 
and variable nuclei that are often kidney-shaped or bilobed; 
cytoplasm containing densely packed or even coalescent large 
granules that stain bright pink, red, or purple in Romanowsky 
stains; and multiple Auer rods [1-4, 10]. Therefore, APL 
can be easily diagnosed at the time of morphologic evaluation. 
However, variant APL t(11;17)(q23;q21) has been reported 
to have atypical APL morphology, and Auer rods are seldom 
observed [9, 10]. Absence of Auer rods or faggot cells is 
especially considered as a characteristic morphologic feature 
of this subtype [9, 10]. In variant APLs, including variant 
RARA translocation, the diagnosis can be made by chromo-Korean J Hematol 2010;45:133-5.
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some analysis or molecular study [11-13]. The results may 
show the typical karyotype t(15;17)(q22;q12); PML-RARA 
or the variant RARA translocation [11-13]. However, in 
our case, the typical morphology of classical APL, including 
multiple Auer rods in numerous leukemic cells and frequent 
faggot cells, was observed, and the karyotype and molecular 
studies showed t(11;17)(q23;q12) and ZBTB16-RARA fusion. 
At the time of morphologic evaluation, our case showed 
findings consistent with those of APL with t(15;17)(q22;q12), 
before chromosome analysis and molecular study were 
performed. The typical immunophenotype of APL has been 
reported to be distinctive unlike those in other acute myeloid 
leukemia (AML) cases. The leukemic cells in the former 
express myeloid antigens such as CD13 and CD33 but show 
weak or negative reaction to CD34 and HLA-DR [14]. Some 
of the microgranular variant APL cases express CD34 and/or 
HLA-DR [15]. However, variant APL with t(11;17)(q23;q12); 
ZBTB16-RARA s u b g r o u p  h a s  b e e n  r e p o r t e d  t o  s h o w  t h e  
same immunophenotype as that in classical APL [10]. 
Interestingly, in our case, the leukemic cells expressed 
HLA-DR in addition to CD13, CD33, and CD117, unlike 
other cases that have previously been reported [10]. The 
variant APL with t(11;17)(q23;q12); ZBTB16-RARA sub-
group usually shows resistance to ATRA therapy [9]. 
Therefore, our patient is being treated with alkylating agents 
rather than the classical APL regimen that includes ATRA.
The present study emphasizes the importance of combining 
morphologic, immunophenotypic, cytogenetic, and molec-
ular studies to distinguish variant APL cases from classical 
APL cases before initiating chemotherapy, regardless of 
whether the morphological study reveals findings consistent 
with those of classical APL.
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